| 摘要 |
<p>This invention describes the new ent-steroids of general formula (I) in which R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R19¿ have the meanings that are indicated in the description, as pharmaceutical active ingredients that in vitro have a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or pronounced action with respect to stimulation of the expression of 5HT2a-receptors and transporters, their production, their therapeutic use and pharmaceutical forms for dispensing, which contain the new compounds. The invention also describes the use of steroids, on which the (8α-H, 9β-H, 10α-H, 13α-H, 14β-H)-gonane skeleton is based, for treatment of estrogen-deficiency-induced diseases and conditions.</p> |
